Sarepta (SRPT) PT Raised to $58 at Jefferies

October 3, 2016 6:42 AM EDT
Get Alerts SRPT Hot Sheet
Price: $45.39 -2.03%

Rating Summary:
    16 Buy, 8 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 26 | New: 7
Trade SRPT Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies analyst Gena Wang reiterated a Hold rating but lifted her price target on Sarepta Therapeutic (NASDAQ: SRPT) to $58.00 (from $50.00).

Wang commented, "Our deep analysis and DD with 4 payer KOLs suggest payers likely will regularly monitor real world benefit for Exondys 51 given its high price tag and a label stating no established clinical benefit. We expect net price in the range of $309-402K (assuming 70% compliance) with majority of pts likely covered by Medicaid. We raise PT to $58 to reflect updated launch assumptions and we believe stock is fairly valued."

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $61.41 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Jefferies & Co, Gena Wang

Add Your Comment